Table 2 AEs of special interest, absolute number (%)

From: Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial

AEs

Any grade

Grade 3/grade 4

Any

62 (100)

61 (98.4)

Neutropenia

57 (91.9)

55 (88.7)

 Febrile neutropenia

10 (16.1)

8 (12.9)

Anemia

47 (75.8)

35 (56.5)

Infectiona

47 (75.8)

14 (22.6)

CRSb

47 (75.8)

4 (6.5)

Thrombocytopenia

46 (74.2)

35 (56.5)

Leukopenia

40 (64.5)

38 (61.3)

Lymphopenia

23 (37.1)

22 (35.5)

Neurotoxicityc

22 (35.5)

1 (1.6)

Second primary malignancy

8 (12.9)

2 (3.2)

  1. aIncludes the SOC infections and infestations.
  2. bCRS uniformly graded per ref. 30.
  3. cGrouped term; events reported ≤8 weeks after infusion. Excludes 1 patient with grade 1 insomnia lasting 251 d.
Back to article page